Are you aware of the latest data on CAR T-cell therapy in myeloma and the implications for our patients? Read my thoughts on this emerging treatment strategy and how I am using these agents in my practice.
What do you tell your patients who are about to receive CAR T-cell treatment? Here are the things I talk about when counseling these patients.
New clinical data are emerging on combining CAR T-cell therapy with checkpoint inhibitors. Here’s my take on the potential of this strategy to improve outcomes in patients who relapsed or never responded to CAR T-cell monotherapy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.